Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis
SYDNEY, Dec. 10, 2024 /PRNewswire/ -- Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with...